STAT3 Antisense and PD-L1 Antibody Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies for cancer, such as those targeting CTLA-4, PD-L1, and OX40, have limited efficacy due to immunosuppressive mechanisms that override PD-1/PD-L1 effects, necessitating the development of combination approaches to enhance anti-tumor immune responses.
Innovation Solution
Combining an immunomodulatory agent, like an anti-PD-L1 antibody or an OX40 agonist, with an antisense compound targeted to STAT3, specifically using AZD9150, to inhibit STAT3 mRNA or protein expression, thereby potentiating immune checkpoint inhibition and enhancing anti-tumor immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunomodulatory agents targeting PD-L1 or CTLA-4 are used, then anti-tumor immune responses are enhanced, but immunosuppressive mechanisms override these effects, limiting overall efficacy
Solution Approach 1:
The patent identifies STAT3 as a key immunosuppressive mechanism that overrides PD-1/PD-L1 effects, and converts this harmful factor into a therapeutic target. By using antisense compounds to specifically inhibit STAT3 expression, the patent transforms the immunosuppressive mechanism into a vulnerability that can be exploited to enhance anti-tumor immunity. This approach directly addresses the limitation of single-agent immunomodulatory therapy by targeting the underlying immunosuppressive driver.
Solution Approach 2:
The patent combines immunomodulatory agents (anti-PD-L1 antibodies, anti-CTLA-4 antibodies, or OX40 agonists) with antisense compounds targeted to STAT3 in a synergistic combination therapy. This merging of two therapeutic approaches with different mechanisms of action overcomes the immunosuppressive barriers that limit single-agent efficacy, thereby enhancing overall anti-tumor immune responses and improving treatment outcomes.
2Ease of operation
If single-agent immunotherapy is used, then treatment simplicity is maintained, but combination approaches are needed to overcome immunosuppression
Solution Approach 1:
The patent merges immunomodulatory agents with STAT3-targeted antisense compounds to create a combination therapy that overcomes immunosuppressive mechanisms. This combination approach, while increasing treatment complexity, significantly improves the reliability of anti-tumor immune responses by addressing multiple immunosuppressive pathways simultaneously.
Data Source
AI summary
The present invention features methods of treating cancer with an immunomodulatory agent, such as an anti-PD-L1 antibody or an antigen-binding fragment thereof, and an antisense compound targeted to STAT3 in a subject in need thereof.